OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and
positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the
treatment of primary open angle glaucoma or ocular hypertension in Chinese subjects. It is
planned that 240 subjects (120 in each group) will be randomly assigned to receive OPC-1085EL
or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.